APWA
RPRX icon

Atlas Private Wealth Advisors’s Royalty Pharma RPRX Stock Holding History

Atlas Private Wealth Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-10
Closed – – 910
2021
Q1 		$0 Buy
+10
New +$474 ﹤0.01% 904

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
SGA
Siguler Guff Advisers New York $56.1M AUM 46.63% 1-Year Est. Return

Atlas Private Wealth Advisors's RPRX Position: Q2 2021 in Review

Atlas Private Wealth Advisors sold out of Royalty Pharma (RPRX) in Q2 2021, closing a stake of 10 shares.

Atlas Private Wealth Advisors first reported a position in RPRX in Q1 2021 and held it in 1 quarter. The position peaked at $0 in Q1 2021. 236 funds tracked by Wall St. Rank hold RPRX as of Q2 2021.

  • Atlas Private Wealth Advisors reported no remaining Royalty Pharma position as of Q2 2021 after selling out during the quarter.
  • Atlas Private Wealth Advisors sold 10 Royalty Pharma shares in Q2 2021.
  • Atlas Private Wealth Advisors first reported a position in Royalty Pharma in Q1 2021 and held it in 1 quarter.
  • Atlas Private Wealth Advisors's Royalty Pharma position peaked at $0 in Q1 2021.
  • 236 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2021.

Based on Atlas Private Wealth Advisors's 13F filing for Q2 2021, filed 2 Aug 2021.